IPHA Fundamental Analysis - INNATE PHARMA SA-SPONS ADR

Name: INNATE PHARMA SA-SPONS ADR (IPHA) Stock
Brand: INNATE PHARMA SA-SPONS ADR
Rating: 3.5 (3 reviews)

Fundamental Rating

Taking everything into account, IPHA scores 2 out of 10 in our fundamental rating. IPHA was compared to 533 industry peers in the Biotechnology industry. Both the profitability and financial health of IPHA have multiple concerns. IPHA has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

IPHA had negative earnings in the past year.

IPHA had a negative operating cash flow in the past year.

IPHA had negative earnings in each of the past 5 years.

In the past 5 years IPHA always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -49.55%, IPHA perfoms like the industry average, outperforming 49.91% of the companies in the same industry.

IPHA has a Return On Equity of -895.24%. This is amonst the worse of the industry: IPHA underperforms 80.68% of its industry peers.

		Industry Rank	Sector Rank
ROA	-49.55%
ROE	-895.24%
ROIC	N/A

ROA(3y)-25.61%

ROA(5y)-23.47%

ROE(3y)-227.3%

ROE(5y)-154.41%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

IPHA's Gross Margin of 49.52% is fine compared to the rest of the industry. IPHA outperforms 75.80% of its industry peers.

In the last couple of years the Gross Margin of IPHA has declined.

The Profit Margin and Operating Margin are not available for IPHA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	49.52%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.49%

GM growth 5Y-4.49%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.

IPHA has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, IPHA has more shares outstanding

IPHA has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -6.42, we must say that IPHA is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of IPHA (-6.42) is worse than 65.48% of its industry peers.

A Debt/Equity ratio of 11.55 is on the high side and indicates that IPHA has dependencies on debt financing.

IPHA has a worse Debt to Equity ratio (11.55) than 83.30% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	11.55
Debt/FCF	N/A
Altman-Z	-6.42

ROIC/WACCN/A

WACC6.73%

2.3 Liquidity

IPHA has a Current Ratio of 2.21. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.

With a Current ratio value of 2.21, IPHA is not doing good in the industry: 72.61% of the companies in the same industry are doing better.

A Quick Ratio of 2.21 indicates that IPHA has no problem at all paying its short term obligations.

IPHA's Quick ratio of 2.21 is on the low side compared to the rest of the industry. IPHA is outperformed by 70.36% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.21
Quick Ratio	2.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for IPHA have decreased strongly by -30.42% in the last year.

Looking at the last year, IPHA shows a very negative growth in Revenue. The Revenue has decreased by -75.86% in the last year.

Measured over the past years, IPHA shows a very negative growth in Revenue. The Revenue has been decreasing by -28.80% on average per year.

EPS 1Y (TTM)-30.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.82%

Revenue 1Y (TTM)-75.86%

Revenue growth 3Y1.38%

Revenue growth 5Y-28.8%

Sales Q2Q%-79.85%

3.2 Future

IPHA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.57% yearly.

IPHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.06% yearly.

EPS Next Y-32.84%

EPS Next 2Y-10.27%

EPS Next 3Y-3.57%

EPS Next 5YN/A

Revenue Next Year-26.21%

Revenue Next 2Y3.03%

Revenue Next 3Y2.3%

Revenue Next 5Y43.06%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPHA. In the last year negative earnings were reported.

Also next year IPHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as IPHA's earnings are expected to decrease with -3.57% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-10.27%

EPS Next 3Y-3.57%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for IPHA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (11/18/2025, 8:15:28 PM)

After market: 1.79 -0.01 (-0.56%)

1.8

-0.02 (-1.1%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-13 2025-11-13/bmo

Earnings (Next)N/A N/A

Inst Owners10.18%

Inst Owner Change-18.25%

Ins Owners0.92%

Ins Owner ChangeN/A

Market Cap165.90M

Revenue(TTM)6.00M

Net Income(TTM)-46.05M

Analysts80

Price Target5.67 (215%)

Short Float %0.09%

Short Ratio0.24

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)4.01%

PT rev (3m)-1.31%

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)-230.42%

EPS NY rev (3m)-753.51%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-18.95%

Revenue NY rev (3m)-67.69%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	23.86
P/FCF	N/A
P/OCF	N/A
P/B	27.83
P/tB	27.83
EV/EBITDA	N/A

EPS(TTM)-0.6

EYN/A

EPS(NY)-0.54

Fwd EYN/A

FCF(TTM)-0.52

FCFYN/A

OCF(TTM)-0.52

OCFYN/A

SpS0.08

BVpS0.06

TBVpS0.06

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-49.55%
ROE	-895.24%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	49.52%
FCFM	N/A

ROA(3y)-25.61%

ROA(5y)-23.47%

ROE(3y)-227.3%

ROE(5y)-154.41%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.49%

GM growth 5Y-4.49%

F-Score1

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	11.55
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	10.84%
Cap/Sales	2.82%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.21
Quick Ratio	2.21
Altman-Z	-6.42

F-Score1

WACC6.73%

ROIC/WACCN/A

Cap/Depr(3y)22.77%

Cap/Depr(5y)23.45%

Cap/Sales(3y)3.3%

Cap/Sales(5y)8.22%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-30.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.82%

EPS Next Y-32.84%

EPS Next 2Y-10.27%

EPS Next 3Y-3.57%

EPS Next 5YN/A

Revenue 1Y (TTM)-75.86%

Revenue growth 3Y1.38%

Revenue growth 5Y-28.8%

Sales Q2Q%-79.85%

Revenue Next Year-26.21%

Revenue Next 2Y3.03%

Revenue Next 3Y2.3%

Revenue Next 5Y43.06%

EBIT growth 1Y-31.37%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year283.08%

EBIT Next 3Y30.44%

EBIT Next 5YN/A

FCF growth 1Y-25.63%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-29.1%

OCF growth 3YN/A

OCF growth 5YN/A

INNATE PHARMA SA-SPONS ADR / IPHA FAQ

What is the ChartMill fundamental rating of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IPHA.

What is the valuation status for IPHA stock?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA-SPONS ADR (IPHA). This can be considered as Overvalued.

What is the profitability of IPHA stock?

INNATE PHARMA SA-SPONS ADR (IPHA) has a profitability rating of 1 / 10.

What is the financial health of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

The financial health rating of INNATE PHARMA SA-SPONS ADR (IPHA) is 2 / 10.

INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

INNATE PHARMA SA-SPONS ADR / IPHA FAQ

What is the ChartMill fundamental rating of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

What is the valuation status for IPHA stock?

What is the profitability of IPHA stock?

What is the financial health of INNATE PHARMA SA-SPONS ADR (IPHA) stock?